Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

A Novel Oral Therapy TTP399 Discovered to Treat Type 1 DiabetesPatients

vTv Therapeutics discovered TTP399 therapy for the treatment of patients with Type 1 diabetes.

TTP399 is a novel, oral, investigational once-daily glucokinase activator. It is considered to be an adjunctive therapy to insulin for the treatment of type 1 diabetes. Moreover, TTP399 shows a significant advantage over other type 1 diabetes therapies.

Low blood sugarlevel being the concern for both doctors and patients providers are apprehensive in utilizing tight glycemic control. Hence, TTP399 therapy offers a potential treatment to an unmet need in the diabetes community.

Type 1 diabetes is a serious, life threateningproblem affecting more than a millionday-to-day. Hypoglycemiais a leading cause of morbidity and potential mortality in the treatment of type 1 diabetes.

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024